Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

OPK

O

OPKO Health, Inc. (OPK)

NMS – Real Time Price. Currency in USD

1.12

-0.05 (-4.27%)

At close: Mar 27, 2026, 4:00 PM EDT

1.12

+0.00 (0.04%)

After-hours: Mar 27, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Here's Why You Should Hold OPK Stock in Your Portfolio for Now

Here's Why You Should Hold OPK Stock in Your Portfolio for Now

OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.

OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts

OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts

OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th.

OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript

OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript

OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript

Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago.

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.

Videos

No Data

There is no data to display

Press releases

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th.

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

This is the third program that s uccessfully combine s Entera's oral peptide N- Tab ® platform with OPKO 's advanced protein chemistry capabilities

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time.